InMIND: Novel standard-of-care for relapsed or refractory follicular lymphoma?

Tafasitamab plus lenalidomide and rituximab outperformed lenalidomide plus rituximab and a placebo in patients with relapsed or refractory follicular lymphoma.

Overall survival data still to be evaluated at 5 years of follow-up

The phase 3 inMIND study (NCT04680052) enrolled 548 patients with relapsed or refractory follicular lymphoma and randomised participants 1:1 to either the CD19-targeting monoclonal antibody tafasitamab or a placebo; both groups also received standard dosing of lenalidomide and rituximab1. Progression-free survival (PFS) was the primary outcome.

After a median follow-up of 14.1 months, the median PFS was 22.4 months in the tafasitamab arm and 13.9 months in the placebo arm, meeting the trial’s primary endpoint (HR 0.43; 95% CI 0.32–0.58; P<0.0001). “This result was consistent in participants with a POD24 status, in participants who were refractory to anti-CD20 therapy, and in participants who had received 2 or more prior lines of therapy,” added Dr Laurie Sehn (The University of British Columbia, Canada). The overall survival data were not yet mature and will be evaluated at 5 years of follow-up.

Neutropenia was the most common grade 3 or higher adverse event in both groups (39.8% vs 37.5%). “The occurrence of grade 3 or 4 pneumonia (8.4% vs 5.1%) and grade 3 or 4 COVID-19 (5.8% vs 2.2%) was numerically higher in the tafasitamab arm,” said Dr Sehn. Besides these events, the safety profiles of the treatment regimens were fairly comparable, according to Dr Sehn.

“This is the first study to validate the approach of combining 2 antibodies for the treatment of follicular lymphoma,” mentioned Dr Sehn. “Tafasitamab plus lenalidomide and rituximab can be administered in the community setting and in the academic setting and has the potential to become a new standard-of-care for patients with relapsed or refractory follicular lymphoma.”

Medical writing support was provided by Robert van den Heuvel.

Source
  1. Sehn LH, et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND). Late-breaking Abstract 1, 66th ASH Annual Meeting, 7–10 December 2024, San Diego, CA, USA.